Acknowledgement
This work was supported by an INHA UNIVERSITY Research Grant to K.K., and National Research Foundation of Korea (NRF) grants funded by the Korean government (MSIT) to K.K. (RS-2023-00208008 and 2021R1A5A2031612), and S.B.L. (2020R1C1C1014281 and 2021R1A5A8029876).
References
- Druker J, Wilson JW, Child F, Shakir D, Fasanya T and Rocha S (2021) Role of hypoxia in the control of the cell cycle. Int J Mol Sci 22, 4874
- Wicks EE and Semenza GL (2022) Hypoxia-inducible factors: cancer progression and clinical translation. J Clin Invest 132, e159839
- Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148, 399-408 https://doi.org/10.1016/j.cell.2012.01.021
- Semenza GL (2000) HIF-1 and human disease: one highly involved factor. Genes Dev 14, 1983-1991 https://doi.org/10.1101/gad.14.16.1983
- Simon MC and Keith B (2008) The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol 9, 285-296 https://doi.org/10.1038/nrm2354
- Semenza GL (2001) HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13, 167-171 https://doi.org/10.1016/S0955-0674(00)00194-0
- Wang GL, Jiang BH, Rue EA and Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92, 5510-5514 https://doi.org/10.1073/pnas.92.12.5510
- Semenza GL (2001) HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107, 1-3 https://doi.org/10.1016/S0092-8674(01)00518-9
- Sutter CH, Laughner E and Semenza GL (2000) Hypoxia-inducible factor 1alpha protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci U S A 97, 4748-4753 https://doi.org/10.1073/pnas.080072497
- Maxwell PH, Wiesener MS, Chang GW et al (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271-275 https://doi.org/10.1038/20459
- Hubbi ME, Gilkes DM, Hu H, Kshitiz, Ahmed I and Semenza GL (2014) Cyclin-dependent kinases regulate lysosomal degradation of hypoxia-inducible factor 1alpha to promote cell-cycle progression. Proc Natl Acad Sci U S A 111, E3325-E3334
- Lee SB, Frattini V, Bansal M et al (2016) An ID2-dependent mechanism for VHL inactivation in cancer. Nature 529, 172-177 https://doi.org/10.1038/nature16475
- Lee SB, Ko A, Oh YT et al (2020) Proline hydroxylation primes protein kinases for autophosphorylation and activation. Mol Cell 79, 376-389 e378
- Manning G, Whyte DB, Martinez R, Hunter T and Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298, 1912-1934 https://doi.org/10.1126/science.1075762
- Aranda S, Laguna A and de la Luna S (2011) DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles. FASEB J 25, 449-462 https://doi.org/10.1096/fj.10-165837
- Lasorella A, Benezra R and Iavarone A (2014) The ID proteins: master regulators of cancer stem cells and tumour aggressiveness. Nat Rev Cancer 14, 77-91 https://doi.org/10.1038/nrc3638
- Gorres KL and Raines RT (2010) Prolyl 4-hydroxylase. Crit Rev Biochem Mol Biol 45, 106-124 https://doi.org/10.3109/10409231003627991
- Kaelin WG, Jr. and Ratcliffe PJ (2008) Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30, 393-402 https://doi.org/10.1016/j.molcel.2008.04.009
- Strowitzki MJ, Cummins EP and Taylor CT (2019) Protein hydroxylation by hypoxia-inducible factor (HIF) hydroxylases: unique or ubiquitous? Cells 8, 384
- Fong GH and Takeda K (2008) Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ 15, 635-641 https://doi.org/10.1038/cdd.2008.10
- Zhong H, Hanrahan C, van der Poel H and Simons JW (2001) Hypoxia-inducible factor 1alpha and 1beta proteins share common signaling pathways in human prostate cancer cells. Biochem Biophys Res Commun 284, 352-356 https://doi.org/10.1006/bbrc.2001.4981
- Reyes H, Reisz-Porszasz S and Hankinson O (1992) Identification of the Ah receptor nuclear translocator protein (Arnt) as a component of the DNA binding form of the Ah receptor. Science 256, 1193-1195 https://doi.org/10.1126/science.256.5060.1193
- Jiang BH, Rue E, Wang GL, Roe R and Semenza GL (1996) Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271, 17771-17778 https://doi.org/10.1074/jbc.271.30.17771
- Varjosalo M, Keskitalo S, Van Drogen A et al (2013) The protein interaction landscape of the human CMGC kinase group. Cell Rep 3, 1306-1320 https://doi.org/10.1016/j.celrep.2013.03.027
- Chowdhury I, Dashi G and Keskitalo S (2023) CMGC kinases in health and cancer. Cancers (Basel) 15, 3838
- Gould CM, Kannan N, Taylor SS and Newton AC (2009) The chaperones Hsp90 and Cdc37 mediate the maturation and stabilization of protein kinase C through a conserved PXXP motif in the C-terminal tail. J Biol Chem 284, 4921-4935 https://doi.org/10.1074/jbc.M808436200
- Lochhead PA (2009) Protein kinase activation loop auto-phosphorylation in cis: overcoming a Catch-22 situation. Sci Signal 2, pe4
- van der Laden J, Soppa U and Becker W (2015) Effect of tyrosine autophosphorylation on catalytic activity and subcellular localisation of homeodomain-interacting protein kinases (HIPK). Cell Commun Signal 13, 3
- Asghar U, Witkiewicz AK, Turner NC and Knudsen ES (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov 14, 130-146 https://doi.org/10.1038/nrd4504
- Malumbres M (2014) Cyclin-dependent kinases. Genome Biol 15, 122
- Lukasik P, Zaluski M and Gutowska I (2021) Cyclin-dependent kinases (CDK) and their role in diseases development-review. Int J Mol Sci 22, 2935
- Ghafouri-Fard S, Khoshbakht T, Hussen BM et al (2022) A review on the role of cyclin dependent kinases in cancers. Cancer Cell Int 22, 325
- Kannan N and Neuwald AF (2004) Evolutionary constraints associated with functional specificity of the CMGC protein kinases MAPK, CDK, GSK, SRPK, DYRK, and CK2alpha. Protein Sci 13, 2059-2077 https://doi.org/10.1110/ps.04637904
- Lim S and Kaldis P (2013) Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 140, 3079-3093 https://doi.org/10.1242/dev.091744
- Ding L, Cao J, Lin W et al (2020) The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci 21, 1960
- Garcia-Reyes B, Kretz AL, Ruff JP et al (2018) The emerging role of cyclin-dependent kinases (CDKs) in pancreatic ductal adenocarcinoma. Int J Mol Sci 19, 3219
- Otto T and Sicinski P (2017) Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer 17, 93-115 https://doi.org/10.1038/nrc.2016.138
- Braicu C, Buse M, Busuioc C et al (2019) A comprehensive review on MAPK: a promising therapeutic target in cancer. Cancers (Basel) 11, 1618
- Johnson GL and Lapadat R (2002) Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298, 1911-1912 https://doi.org/10.1126/science.1072682
- Cargnello M and Roux PP (2011) Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 75, 50-83 https://doi.org/10.1128/MMBR.00031-10
- Burotto M, Chiou VL, Lee JM and Kohn EC (2014) The MAPK pathway across different malignancies: a new perspective. Cancer 120, 3446-3456 https://doi.org/10.1002/cncr.28864
- Murphy LO, Smith S, Chen RH, Fingar DC and Blenis J (2002) Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 4, 556-564 https://doi.org/10.1038/ncb822
- Fojtik P, Beckerova D, Holomkova K, Senfluk M and Rotrekl V (2020) Both hypoxia-inducible factor 1 and MAPK signaling pathway attenuate PI3K/AKT via suppression of reactive oxygen species in human pluripotent stem cells. Front Cell Dev Biol 8, 607444
- Lee KH, Choi EY, Hyun MS and Kim JR (2004) Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4. Exp Mol Med 36, 57-64 https://doi.org/10.1038/emm.2004.8
- Sang N, Stiehl DP, Bohensky J, Leshchinsky I, Srinivas V and Caro J (2003) MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J Biol Chem 278, 14013-14019 https://doi.org/10.1074/jbc.M209702200
- Ren H, Accili D and Duan C (2010) Hypoxia converts the myogenic action of insulin-like growth factors into mitogenic action by differentially regulating multiple signaling pathways. Proc Natl Acad Sci U S A 107, 5857-5862 https://doi.org/10.1073/pnas.0909570107
- Wang Y, Huang Y, Guan F et al (2013) Hypoxia-inducible factor-1alpha and MAPK co-regulate activation of hepatic stellate cells upon hypoxia stimulation. PLoS One 8, e74051
- Park EC and Rongo C (2016) The p38 MAP kinase pathway modulates the hypoxia response and glutamate receptor trafficking in aging neurons. Elife 5, e12010
- Flugel D, Gorlach A, Michiels C and Kietzmann T (2007) Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol Cell Biol 27, 3253-3265 https://doi.org/10.1128/MCB.00015-07
- Song M, Pang L, Zhang M, Qu Y, Laster KV and Dong Z (2023) Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases. Signal Transduct Target Ther 8, 148
- Bowler E, Porazinski S, Uzor S et al (2018) Hypoxia leads to significant changes in alternative splicing and elevated expression of CLK splice factor kinases in PC3 prostate cancer cells. BMC Cancer 18, 355
- Becker W (2012) Emerging role of DYRK family protein kinases as regulators of protein stability in cell cycle control. Cell Cycle 11, 3389-3394 https://doi.org/10.4161/cc.21404
- Hammerle B, Ulin E, Guimera J, Becker W, Guillemot F and Tejedor FJ (2011) Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling. Development 138, 2543-2554 https://doi.org/10.1242/dev.066167
- Litovchick L, Florens LA, Swanson SK, Washburn MP and DeCaprio JA (2011) DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly. Genes Dev 25, 801-813 https://doi.org/10.1101/gad.2034211
- Park J, Oh Y, Yoo L et al (2010) Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells. J Biol Chem 285, 31895-31906 https://doi.org/10.1074/jbc.M110.147520
- Yabut O, Domogauer J and D'Arcangelo G (2010) Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells. J Neurosci 30, 4004-4014 https://doi.org/10.1523/JNEUROSCI.4711-09.2010
- Dowjat WK, Adayev T, Kuchna I et al (2007) Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome. Neurosci Lett 413, 77-81 https://doi.org/10.1016/j.neulet.2006.11.026
- Soundararajan M, Roos AK, Savitsky P et al (2013) Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition. Structure 21, 986-996 https://doi.org/10.1016/j.str.2013.03.012
- Himpel S, Panzer P, Eirmbter K et al (2001) Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. Biochem J 359, 497-505 https://doi.org/10.1042/bj3590497
- Becker W and Joost HG (1999) Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity. Prog Nucleic Acid Res Mol Biol 62, 1-17
- Mercer SE and Friedman E (2006) Mirk/Dyrk1B: a multifunctional dual-specificity kinase involved in growth arrest, differentiation, and cell survival. Cell Biochem Biophys 45, 303-315 https://doi.org/10.1385/CBB:45:3:303
- Cockman ME, Lippl K, Tian YM et al (2019) Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates. Elife 8, e46490
- Epstein AC, Gleadle JM, McNeill LA et al (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54 https://doi.org/10.1016/S0092-8674(01)00507-4
- Zhang H, Wu W, Du Y et al (2004) Hsp90/p50cdc37 is required for mixed-lineage kinase (MLK) 3 signaling. J Biol Chem 279, 19457-19463 https://doi.org/10.1074/jbc.M311377200
- Grammatikakis N, Lin JH, Grammatikakis A, Tsichlis PN and Cochran BH (1999) p50(cdc37) acting in concert with Hsp90 is required for Raf-1 function. Mol Cell Biol 19, 1661-1672 https://doi.org/10.1128/MCB.19.3.1661
- Papenfuss M, Lutzow S, Wilms G et al (2022) Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B. Sci Rep 12, 2393
- Walte A, Ruben K, Birner-Gruenberger R et al (2013) Mechanism of dual specificity kinase activity of DYRK1A. FEBS J 280, 4495-4511 https://doi.org/10.1111/febs.12411
- Lochhead PA, Sibbet G, Morrice N and Cleghon V (2005) Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs. Cell 121, 925-936 https://doi.org/10.1016/j.cell.2005.03.034
- Wang L, Zhang Q and You Q (2022) Targeting the HSP90-CDC37-kinase chaperone cycle: a promising therapeutic strategy for cancer. Med Res Rev 42, 156-182 https://doi.org/10.1002/med.21807
- Wang L, Li L, Gu K, Xu XL, Sun Y and You QD (2017) Targeting Hsp90-Cdc37: a promising therapeutic strategy by inhibiting Hsp90 chaperone function. Curr Drug Targets 18, 1572-1585 https://doi.org/10.2174/1389450117666160527125522